(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter. Most Read from Bloomberg ...
Novo Holdings’ deal will see the Danish fund manager fork over $16.5 billion for Catalent, which operates dozens of production sites across Asia, Europe, Latin America and North America. The ...
Danaher Corporation is a leading player in the life science industry, with strong financial performance despite many spin-offs. The healthcare industry is facing challenges due to weak funding and ...
Danaher Corp (NYSE: DHR) has logged Q1 FY23 adjusted EPS of $2.36, down from $2.76 a year ago, surpassing the consensus of $2.25. Sales decreased 7% Y/Y to $7.17 billion, beating the consensus of ...
Danaher Corporation DHR is well poised for growth courtesy of strength across its end markets, strategic acquisitions and its focus on improving the product line and operational excellence.
Deep-pocketed investors have adopted a bearish approach towards Danaher DHR, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
LONDON, April 12 (Reuters Breakingviews) - For any ambitious M&A adviser, there’s obvious appeal in pitching clients on a potential takeover of BP (BP.L) , opens new tab. The $110 billion energy ...
Danaher DHR has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 16.94%. Currently, Danaher has a market capitalization of $186.08 ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...
The most recent trading session ended with Danaher (DHR) standing at $253.10, reflecting a +0.12% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 1.12%.